Hematopoietic stem cell transplantation and immunotherapy for pediatric acute myeloid leukemia: an open challenge

References

• Creutzig U, van den Heuvel-Eibrink MM, Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood 2012;120(16):3187-205
   PubMed Web of Science ®Google Scholar
• Kaspers GJL. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther 2012;12(3):405-13
   PubMed Web of Science ®Google Scholar
• Pession A, Masetti R, Rizzari C, et al. Results of the AIEOP AML 2002/01 multicenter prospective trial for the treatment of children with acute myeloid leukemia. Blood 2013;122(2):170-8
   PubMed Web of Science ®Google Scholar
• Imamura T, Iwamoto S, Kanai R, et al. Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study. Br J Haematol 2012;159(2):204-10
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11(6):543-52
   PubMed Web of Science ®Google Scholar
• Gibson BES, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2010;19(12):2130-8
   Google Scholar
• Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol 2011;29(3):310-15
   PubMed Web of Science ®Google Scholar
• Sanders JE, Thomas ED, Buckner CD, et al. Marrow transplantation for children in first remission of acute nonlymphoblastic leukemia: an update. Blood 1985;66(2):460-2
   PubMed Web of Science ®Google Scholar
• Koreth J, Schlenk R, Kopecky KJ, et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009;301(22):2349-61
   PubMed Web of Science ®Google Scholar
• Burnett AK, Goldstone A, Hills RK, et al. Curability of Patients With Acute Myeloid Leukemia Who Did Not Undergo Transplantation in First Remission. J Clin Oncol 2013;31(10):1293-301
   PubMed Web of Science ®Google Scholar
• Niewerth D, Creutzig U, Bierings MB, Kaspers GJL. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood 2010;116(13):1-11
   Google Scholar
• Burke MJ, Wagner JE, Cao Q, et al. Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. Biol Blood Marrow Transplant 2013;19(7):1021-5
   Google Scholar
• Koh KN, Park M, Kim BE, et al. Favorable outcomes after allogeneic hematopoietic stem cell transplantation in children with high-risk or advanced acute myeloid leukemia. J Pediatr Hematol Oncol 2010;33(4):281-8
   Google Scholar
• Klusmann JH, Reinhardt D, Zimmermann M, et al. The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study. Haematologica 2011;97(1):21-9
   Google Scholar
• Paietta E. Minimal residual disease in acute myeloid leukemia: coming of age. Hematology Am Soc Hematol Educ Program 2012;2012:35-42
   PubMedGoogle Scholar
• Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 2012;119(2):332-41
   PubMed Web of Science ®Google Scholar
• Loken MR, Alonzo TA, Pardo L, et al. Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group. Blood 2012;120(8):1581-8
   PubMed Web of Science ®Google Scholar
• Carpenter PA, Meshinchi S, Davies SM. Transplantation for AML in Children. Biol Blood Marrow Transplant 2012;18(Suppl):S33-9
   Google Scholar
• Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood 2009;19:4293-9
   Google Scholar
• Wagner JE, Eapen M, Carter SL, et al. No survival advantage after double umbilical cord blood (UCB) compared to single UCB transplant in children with hematological malignancy: results of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 0501) Randomized Trial. ASH Annual Meeting Abstracts 2012;120:359
   Google Scholar
• Velardi A. Role of KIRs and KIR ligands in hematopoietic transplantation. Curr Opin Immunol 2008;20(5):581-7
   PubMed Web of Science ®Google Scholar
• Lowe EJ, Turner V, Handgretinger R, et al. T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation. Br J Haematol 2003;123(2):323-6
   PubMedGoogle Scholar
• Venstrom JM, Pittari G, Gooley TA, et al. HLA-C–Dependent Prevention of Leukemia Relapse by Donor Activating KIR2DS1. N Engl J Med 2012;367(9):805-16
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Shem-Tov N, et al. Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity. Leukemia 2006;20(2):322-8
   PubMed Web of Science ®Google Scholar
• de Berranger E, Cousien A, Petit A, et al. Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Bone Marrow Transplant 2013. [Epub ahead of print]
   Google Scholar
• Chevallier P, Labopin M, Buchholz S, et al. Clofarabine-containing conditioning regimen for allo-SCT in AML/ALL patients: a survey from the Acute Leukemia Working Party of EBMT. Eur J Haematol 2012;89(3):214-19
   PubMedGoogle Scholar
• Nemecek ER, Guthrie KA, Sorror ML, et al. Conditioning with treosulfan and fludarabine followed by allogeneic hematopoietic cell transplantation for high-risk hematologic malignancies. Biol Blood Marrow Transplant 2011;17(3):341-50
   PubMedGoogle Scholar
• Schlegel P, Teltschik H-M, Pfeiffer M, et al. Long-term IL-2 therapy after transplantation of T cell depleted stem cells from alternative donors in children. Best Pract Res Clin Haematol 2011;24(3):443-52
   Google Scholar
• Pautas C, Merabet F, Thomas X, et al. Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study. J Clin Oncol 2010;28(5):808-14
   PubMed Web of Science ®Google Scholar
• Brune M, Castaigne S, Catalano J, et al. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial. Blood 2006;108(1):88-96
   PubMed Web of Science ®Google Scholar
• Rubnitz JE, Inaba H, Ribeiro RC, et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. J Clin Oncol 2010;28(6):955-9
   PubMed Web of Science ®Google Scholar
• Kubal T, Lancet JE. The thorny issue of relapsed acute myeloid leukemia. Curr Opin Hematol 2013;20(2):100-6
   Google Scholar
• Savani BN, Mielke S, Reddy N, et al. Management of relapse after allo-SCT for AML and the role of second transplantation. Bone Marrow Transplant 2009;44(12):769-77
   Google Scholar
• Nishikawa T, Inagaki J, Nagatoshi Y, et al. The second therapeutic trial for children with hematological malignancies who relapsed after their first allogeneic SCT: long-term outcomes. Pediatr Transplant 2012;16(7):722-8
   Google Scholar
• Levine J, Barrett A, Zhang MJ, et al. Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. Bone Marrow Transplant 2008;42(3):201-5
   Google Scholar
• Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT acute leukemia working party. J Clin Oncol 2007;25(31):4938-45
   PubMed Web of Science ®Google Scholar
• Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol 2013;91(4):304-14
   PubMed Web of Science ®Google Scholar
• Ivanoff S, Gruson B, Chantepie SP, et al. 5-Azacytidine treatment for relapsed or refractory acute myeloid leukemia after intensive chemotherapy. Am J Hematol 2013;88(7):601-5
   Google Scholar
• Phillips CL, Davies SM, McMasters R, et al. Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. Br J Haematol 2013;161(3):406-10
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism defines a high-risk group of childhood acute myelogenous leukemia patients after allogeneic stem cell transplantation where pre-emptive immunotherapy may be effective. Bone Marrow Transplant 2004;33(8):815-21
   PubMed Web of Science ®Google Scholar
• Bader P, Kreyenberg H, Hoelle W, et al. Increasing mixed chimerism is an important prognostic factor for unfavorable outcome in children with acute lymphoblastic leukemia after allogeneic stem-cell transplantation: possible role for pre-emptive immunotherapy? J Clin Oncol 2004;22(9):1696-705
   Google Scholar
• Bader P, Klingebiel T, Schaudt A, et al. Prevention of relapse in pediatric patients with acute leukemias and MDS after allogeneic SCT by early immunotherapy initiated on the basis of increasing mixed chimerism: a single center experience of 12 children. Leukemia 1999;13(12):2079-86
   Google Scholar
• Rettinger E, Willasch AM, Kreyenberg H, et al. Preemptive immunotherapy in childhood acute myeloid leukemia for patients showing evidence of mixed chimerism after allogeneic stem cell transplantation. Blood 2011;118(20):5681-8
   PubMed Web of Science ®Google Scholar
• Yan CH, Liu DH, Liu KY, et al. Risk stratification–directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood 2012;119(14):3256-62
   PubMed Web of Science ®Google Scholar
• Krishnamurthy P, Potter VT, Barber LD, et al. Outcome of donor lymphocyte infusion after t cell-depleted allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant 2013;19(4):562-8
   PubMed Web of Science ®Google Scholar
• Introna M, Franceschetti M, Ciocca A, et al. Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation. Bone Marrow Transplant 2006;38(9):621-7
   PubMed Web of Science ®Google Scholar
• Rettinger E, Meyer V, Kreyenberg H, et al. Cytotoxic Capacity of IL-15-Stimulated Cytokine-Induced Killer Cells Against Human Acute Myeloid Leukemia and Rhabdomyosarcoma in Humanized Preclinical Mouse Models. Front Oncol 2012;9:2-32
   Google Scholar
• Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007;92(7):952-9
   PubMed Web of Science ®Google Scholar
• Laport GG, Sheehan K, Baker J, et al. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2011;17(11):1679-87
   PubMed Web of Science ®Google Scholar
• Linn YC, Niam M, Chu S, et al. The anti-tumor activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies. Bone Marrow Transplant 2012;1(47):957-66
   Google Scholar
• Dutour A, Marin V, Pizzitola I, et al. In vitro and in vivo antitumor effect of anti-CD33 chimeric receptor-expressing EBV-CTL against CD33 acute myeloid leukemia. Adv Hematol 2012;2012:683065
   PubMedGoogle Scholar
• Tettamanti S, Marin V, Pizzitola I, et al. Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor. Br J Haematol 2013;161(3):389-401
   PubMed Web of Science ®Google Scholar
• Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368(16):1509-18
   PubMed Web of Science ®Google Scholar
• Rezvani K. Posttransplantation Vaccination: concepts Today and on the Horizon. `Hematology Am Soc Hematol Educ Program 2011;2011:299-304
   PubMedGoogle Scholar
• Anguille S, Van Tendeloo VF, Berneman ZN. Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia. Leukemia 2012;26(10):2186-96
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008;111(1):236-42
   PubMed Web of Science ®Google Scholar
• Rezvani K, Yong AS, Mielke S, et al. Repeated PR1 and WT1 peptide vaccination in Montanide-adjuvant fails to induce sustained high-avidity, epitope-specific CD8+ T cells in myeloid malignancies. Haematologica 2011;96(3):432-40
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Wieder ED, Thall PF, et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia [Abstract]. Blood 2007;110:283
   Google Scholar
• Oka Y, Tsuboi A, Taguchi T, et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004;101(38):13885-90
   PubMed Web of Science ®Google Scholar
• Keilholz U, Letsch A, Busse A, et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009;113(26):6541-8
   PubMed Web of Science ®Google Scholar
• Maslak PG, Dao T, Krug LM, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116(2):171-9
   PubMed Web of Science ®Google Scholar
• Brody JD, Goldstein MJ, Czerwinski DK, Levy R. Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors. Blood 2009;113(1):85-94
   PubMed Web of Science ®Google Scholar
• Ho VT, Vanneman M, Kim H, et al. Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation. Proc Natl Acad Sci USA 2009;106(37):15825-30
   PubMed Web of Science ®Google Scholar
• Stadtmauer EA, Vogl DT, Luning Prak E, et al. Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 2011;117(1):63-71
   PubMedGoogle Scholar
• Rapoport AP, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma. Blood 2011;117(3):788-97
   PubMed Web of Science ®Google Scholar
• Borrello IM, Levitsky HI, Stock W, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood 2009;114:1736-45
   PubMed Web of Science ®Google Scholar
• Kwak LW, Taub DD, Duffey PL, et al. Transfer of myeloma idiotype-specific immunity from an actively immunized marrow donor. Lancet 1995;345(8956):1016-20
   PubMed Web of Science ®Google Scholar
• Anguille S, Lion E, Smits E, et al. Dendritic cell vaccine therapy for acute myeloid leukemia: questions and answers. Hum Vaccin 2011;7(5):579-84
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Lancet JE, Wood BL, et al. Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica 2013;98(1):119-28
   PubMed Web of Science ®Google Scholar
• Bross PF, Beitu J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001;7(6):1490-6
   PubMed Web of Science ®Google Scholar
• Takeshita A. Efficacy and resistance of gemtuzumab ozogamicin for acute myeloid leukemia. Int J Hematol 2013;97(6):703-16
   PubMed Web of Science ®Google Scholar
• Satwani P, Bhatia M, Garvin JH Jr, et al. A phase I study of gemtuzumab ozogamicin (GO) in combination with busulfan and cyclophosphamide (Bu/Cy) and allogeneic stem cell transplantation in children with poor-risk CD33+ AML: a new targeted immunochemotherapy myeloablative conditioning (MAC) regimen. Biol Blood Marrow Transplant 2012;18(2):324–329
   Google Scholar
• Snauwaert S, Vandekerckhove B, Kerre T. Can immunotherapy specifically target acute myeloid leukemic stem cells? Oncoimmunology 2013;2(2):e22943
   Google Scholar